These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 21118169)
1. [The program of lowering of residual vascular risk (The Residual Vascular Risk Reduction Initiative). Part II. Methods of correction]. Zubareva MIu; Susekov AV Kardiologiia; 2010; 50(9):64-70. PubMed ID: 21118169 [No Abstract] [Full Text] [Related]
3. [The program of lowering of residual risk (the residual risk reduction initiative). Part I. Factors of residual risk]. Zubareva MIu; Susekov AV Kardiologiia; 2010; 50(8):76-83. PubMed ID: 21105333 [TBL] [Abstract][Full Text] [Related]
5. The metabolic and pharmacologic bases for treating atherogenic dyslipidaemia. Chan DC; Barrett PH; Watts GF Best Pract Res Clin Endocrinol Metab; 2014 Jun; 28(3):369-85. PubMed ID: 24840265 [TBL] [Abstract][Full Text] [Related]
6. [Lipid management--treatment goal and strategy]. Koshiyama H Nihon Rinsho; 2006 Nov; 64(11):2102-6. PubMed ID: 17087303 [TBL] [Abstract][Full Text] [Related]
7. Dyslipidemia Part 2: Review of Dyslipidemia Treatment in Patients With Noncoronary Vascular Disease. Gonzalez L; Helkin A; Gahtan V Vasc Endovascular Surg; 2016 Feb; 50(2):119-35. PubMed ID: 26983668 [TBL] [Abstract][Full Text] [Related]
8. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). ; Catapano AL; Reiner Z; De Backer G; Graham I; Taskinen MR; Wiklund O; Agewall S; Alegria E; Chapman MJ; Durrington P; Erdine S; Halcox J; Hobbs R; Kjekshus J; Perrone Filardi P; Riccardi G; Storey RF; Wood D; Atherosclerosis; 2011 Jul; 217 Suppl 1():S1-44. PubMed ID: 21723445 [No Abstract] [Full Text] [Related]
9. [Place of fibrates for the treatment of patients with atherogenic dyslipidemia]. Ducobu J; Scheen AJ; Legat P; De Backer G; Van Gaal L; Velkeniers B; Kartounian J; Maes M; Hermans M Rev Med Liege; 2009 Oct; 64(10):512-8. PubMed ID: 19911665 [TBL] [Abstract][Full Text] [Related]
10. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. Urban D; Pöss J; Böhm M; Laufs U J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703 [TBL] [Abstract][Full Text] [Related]
11. [Dyslipidaemia and vascular risk. A new evidence based review]. Pallarés-Carratalá V; Pascual-Fuster V; Godoy-Rocatí D Semergen; 2015; 41(8):435-45. PubMed ID: 25559484 [TBL] [Abstract][Full Text] [Related]
12. [Part I. Fibrates in primary and secondary prevention]. Clin Investig Arterioscler; 2016 Jul; 28 Suppl 3():3-10. PubMed ID: 27473465 [No Abstract] [Full Text] [Related]
13. Triglycerides: how much credit do they deserve? Kohli P; Cannon CP Med Clin North Am; 2012 Jan; 96(1):39-55. PubMed ID: 22391250 [TBL] [Abstract][Full Text] [Related]
20. An International Atherosclerosis Society position paper: global recommendations for the management of dyslipidemia: executive summary. Expert Panel on Dyslipidemia Atherosclerosis; 2014 Feb; 232(2):410-3. PubMed ID: 24468156 [No Abstract] [Full Text] [Related] [Next] [New Search]